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http://dx.doi.org/10.1016/j.ccr.2013.08.004SUMMARYRAS genes are commonly mutated in cancer; however, RAS mutations are rare in breast cancer, despite
frequent hyperactivation of Ras and ERK. Here, we report that the RasGAP gene, RASAL2, functions as a
tumor and metastasis suppressor. RASAL2 is mutated or suppressed in human breast cancer, and RASAL2
ablation promotes tumor growth, progression, and metastasis in mouse models. In human breast cancer,
RASAL2 loss is associated with metastatic disease; low RASAL2 levels correlate with recurrence of luminal
B tumors; and RASAL2 ablation promotes metastasis of luminal mouse tumors. Additional data reveal a
broader role for RASAL2 inactivation in other tumor types. These studies highlight the expanding role of
RasGAPs and reveal an alternative mechanism of activating Ras in cancer.INTRODUCTION
TheRas pathway is one of themost commonly deregulated path-
ways in human cancer (Downward, 2003). Mutations in RAS
genes occur in a variety of tumor types (Karnoub and Weinberg,
2008; Pylayeva-Gupta et al., 2011); however, the Ras pathway
is also frequently activated as a consequence of alterations in up-
stream regulators and downstream effectors, underscoring the
importance of this pathway in cancer (Downward, 2003).
Ras is negatively regulated by Ras GTPase-activating proteins
(RasGAPs), which catalyze the hydrolysis of Ras-GTP to Ras-
GDP (Bernards, 2003). As such, RasGAPs are poised to function
aspotential tumorsuppressors. Indeed, theNF1 tumorsuppressor
encodesaRasGAPand ismutated in the familial cancer syndromeSignificance
The RasGAPs are direct negative regulators of Ras and are th
Here, we identify a RasGAP gene, RASAL2, as a tumor suppre
loss plays a causal role in the development, progression, andm
metastasis of other solid tumors as well. Collectively, these da
activated in cancer and identify a role for RASAL2 and Ras in
Caneurofibromatosis type 1 (Cawthon et al., 1990).NF1 also is lost or
suppressed in sporadic cancers, including glioblastoma (Cancer
Genome Atlas Research Network, 2008; Parsons et al., 2008;
McGillicuddy et al., 2009), nonsmall cell lung cancer (Ding et al.,
2008), neuroblastoma (Ho¨lzel et al., 2010), and melanoma (Kraut-
hammer et al., 2012; Maertens et al., 2012). More recently, the
RasGAPgene,DAB2IP, hasbeenshown to functionasapotent tu-
mor and metastasis suppressor in prostate cancer (Min et al.,
2010). In total, there are 14 RasGAP genes in the human genome
(Bernards, 2003). All contain a RasGAP domain but exhibit little
similarity elsewhere. It is currently unknown whether any of these
other genes may also function as human tumor suppressors.
Breast cancer is the most common cancer in women world-
wide (Kamangar et al., 2006). K-, H-, and N-RAS mutations areerefore poised to function as potential tumor suppressors.
ssor within this gene family. Our data suggest that RASAL2
etastasis of breast cancer andmay play a broader role in the
ta reveal an alternative mechanism by which Ras becomes
breast cancer progression and metastasis.
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Figure 1. RASAL2 Is a Candidate Tumor
Suppressor
(A) Left: immortalized MEFs were infected with
lentiviral shRNAs that target Rasal2, Nf1, or control
and were plated in soft agar. Data are reported as
relative number of colonies ± SEM. Inactivation of
Nf1 or Rasal2 induced a statistically significant in-
crease in anchorage-independent growth (p %
0.0001).Right:westernblot confirmingknockdown.
(B) RASAL2 mutations in human tumor samples
(Bamford et al., 2004). Each triangle represents a
nonsynonymous mutation. Red triangles indicate
breast cancer mutations. See also Tables S1
and S2.
(C) RASAL2 expression in a panel of human breast
cancer cell lines in comparison to normal human
mammary epithelial cells. Cell lines with very low
or no RASAL2 are starred. Luminal (Lu) or basal
(Ba) subtype categorization is indicated.
(D)RelativeRASAL2expression insubsetsof sorted
human mammary epithelial cells (Lim et al., 2009).
MaSC, mammary stem cell enriched: (CD49hi
EpCAM). LP: luminal progenitor (CD49f+EpCAM+).
ML, mature luminal (CD49f EpCAM+). Data show
relative expression ± SD. Similar results were
obtained using two additional RASAL2 probes.
There were no statistically significant differences
in RASAL2 expression between subsets of cells.
(E)Left:westernblot ofRas-GTPandphospho-ERK
(pERK) levels in MCF7 cells following expression of
LacZ or RASAL2. Right: western blot of Ras-GTP
and phospho-ERK (pERK) levels in MCF10A cells
following shRNA-mediated inactivation of RASAL2
or control (nontargeting ‘‘Scramble’’ shRNA).
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RASAL2: A Tumor Suppressor that Regulates Rasrelatively rare in this tumor type, and together they have been
detected in only 3.2% of all breast lesions (Bamford et al.,
2004). Nevertheless, the Ras/ERK pathway is hyperactivated
in R50% of breast cancers and has been proposed to be
involved in tumor progression and recurrence, suggesting
that Ras may be more frequently activated by other mecha-
nisms in these tumors (Sivaraman et al., 1997; von Lintig
et al., 2000; Mueller et al., 2000). In this study, we demonstrate
that the RasGAP gene, RASAL2, functions as a tumor sup-
pressor in breast cancer. Through the analysis of human tumor
samples, human xenografts, and genetically engineered
mouse models, we show that RASAL2 loss plays a causal
role in breast cancer development and metastasis. Additional
mouse modeling studies reveal a broader potential role for
RASAL2 in other tumor types. Together, these studies highlight
the expanding role of RasGAP genes in cancer and reveal an
important mechanism by which Ras becomes activated in
breast tumors.366 Cancer Cell 24, 365–378, September 9, 2013 ª2013 Elsevier Inc.RESULTS
The RasGAP Gene, RASAL2, Is a
Candidate Tumor Suppressor
We previously developed a cell-based
screen to identify additional RasGAPs
that might function as tumor suppressors
(Min et al., 2010). Distinct small hairpinRNAs (shRNAs) that recognize individual RasGAP genes were
introduced into immortalized mouse embryonic fibroblasts
(MEFs), and cells were evaluated for the ability to grow in soft
agar. Three genes scored in this screen:Nf1, a well-documented
tumor suppressor gene, Dab2ip, which we have since shown is
a tumor suppressor in prostate cancer, and Rasal2, a third
RasGAP gene (Min et al., 2010). Several Rasal2-specific shRNA
sequences promoted colony growth in this assay and did so as
well as Nf1- and Dab2ip-specific shRNAs (Figure 1A; Min et al.,
2010). Notably, transformation was not generally promoted by
the loss of any RasGAP, suggesting that only a subset of
RasGAPs may function as tumor suppressors (Min et al.,
2010). Upon identifying RASAL2 as a candidate tumor suppres-
sor, we searched publicly available databases and found muta-
tions within the catalytic RasGAP domain in human breast
cancers (Figure 1B; Table S1 available online) (Sjo¨blom et al.,
2006; Shah et al., 2012). Current genomic mutation databases
indicate that RASAL2 is also mutated in several other tumor
Cancer Cell
RASAL2: A Tumor Suppressor that Regulates Rastypes, including colorectal, lung, and ovarian tumors (Figure 1B;
Table S2). In total, 42 nonsynonymous mutations have been
detected in RASAL2, 31% of which reside in the catalytic
RasGAP domain, many of which are predicted to be deleterious
(Tables S2 and S3). Because the mechanism by which Ras
becomes activated in breast cancer is largely unknown, and
because mutations in breast tumors were among the first to be
identified, we began by investigating a potential role for RASAL2
inactivation in breast cancer development.
Work from our laboratory and others have shown that the Ras-
GAP genes NF1 and DAB2IP are inactivated in cancer by ge-
netic, epigenetic, and proteasomal mechanisms (Dote et al.,
2004; McGillicuddy et al., 2009; Min et al., 2010). Moreover, in
many instances the nongenetic mechanisms of inactivation of
these tumor suppressors appear to be more prevalent than
mutational events in sporadic tumors (McGillicuddy et al.,
2009; Min et al., 2010; Maertens et al., 2012). Therefore, we
began by examining RASAL2 protein expression in a panel of
breast cancer cell lines. In comparison to normal mammary
epithelial cells, in at least 5 out of 15 breast cancer cell lines
RASAL2 was absent or minimally expressed, suggesting that
RASAL2may be lost or suppressed in this tumor type (Figure 1C).
RASAL2 levels were high in MDA-MB-231 and SUM159PT cells,
which are known to harbor mutations in KRAS and HRAS,
respectively (Hollestelle et al., 2007). We also noted that RASAL2
was frequently absent in cells derived from luminal cancers in
this panel of lines. Cell sorting studies indicate that there are
no inherent differences in RASAL2 expression in any specific
cell population within the mammary cell hierarchy: luminal pro-
genitor, mature luminal, or mammary stem cell enriched, sug-
gesting that the low RASAL2 levels associated with luminal can-
cer cell lines are not inherently associated with a pre-existing
reduction in RASAL2 levels due to a specific cell of origin or
fate, as has been suggested for other genes (Figure 1D) (Lim
et al., 2009). When RASAL2 was reconstituted in MCF7 cells,
which express little to no endogenous RASAL2, Ras-GTP and
phospho-ERK levels were suppressed (Figure 1E). Conversely,
acute inactivation of RASAL2 via shRNA sequences in immortal-
izedmammary epithelial cells (MCF10A) increased Ras-GTP and
phospho-ERK levels (Figure 1E). These data confirm that
RASAL2 is a functional RasGAP and that loss of RASAL2 acti-
vates Ras and ERK in this tumor type.
RASAL2 Functions as a Tumor Suppressor in Breast
Cancer
We next investigated the biological consequences of reconsti-
tuting or suppressing RASAL2 in breast cancer cell lines. When
RASAL2 was introduced into human breast cancer cells that
lack endogenous RASAL2, proliferation was largely unaffected
(Figure 2A); however, RASAL2 reconstitution significantly in-
hibited anchorage-independent colony growth (Figure 2B). In
contrast, RASAL2 did not inhibit colony growth of SUM159PT
cells, which retain RASAL2 expression but harbor an activating
RAS mutation (Figure 2B). RASAL2 also potently suppressed
the growth of RASAL2-deficient breast cancer xenografts in vivo
but again had no effect on RAS mutant tumors (Figure 2C).
Conversely, shRNA-mediated suppression of endogenous
RASAL2 in a breast cancer cell line that normally does not
grow well as a xenograft promoted tumor growth in vivo (Fig-Caure 2D). Together, these gain- and loss-of-function studies sug-
gest that RASAL2 can function as a tumor suppressor in the
mammary epithelium and that inactivation or loss of RASAL2
can contribute to mammary tumor development. Notably, like
NF1 and DAB2IP, RASAL2 appears to restrict transformation
and/or anchorage-independent growth, rather than generally
suppressing cell proliferation in two-dimensional culture sys-
tems (Johannessen et al., 2005; Min et al., 2010).
RASAL2 Functions via Its Effects on Ras
To determine whether the RasGAP domain of RASAL2 and ef-
fects on Ras were critical for tumor suppression, we first evalu-
ated the effects of RASAL2mutations identified in human breast
cancer samples. Two of the three RasGAP domain mutants
(K417E and K567X) failed to suppress anchorage-independent
growth, demonstrating that these two mutations result in a clear
loss of function (Figure 3A). The third mutation, which resulted in
a more conservative amino acid change (E509D), still retained
activity in this assay and therefore does not appear to be patho-
genic; however, a number of additional nonconservative muta-
tions have been detected in the RasGAP domain in other tumor
types (Table S3). Consistent with these biological observations,
both the K417E and the K567X mutations were defective in their
ability to suppress activation of the Ras/ERK pathway (Fig-
ure 3B). Phospho-ERK levels in xenograft tumors further illus-
trate the difference in activity between pathogenic and
nonpathogenic mutations (Figure 3C). To complement these
studies, we investigated which Ras isoforms were activated in
response to RASAL2 suppression and found that both K-Ras
and H-Ras-GTP levels were elevated (Figure 3D). Accordingly,
ablation of either KRAS or HRAS suppressed colony growth by
more than 50% (Figure 3E). Together, these results demonstrate
that the RasGAP domain is essential for RASAL2 tumor suppres-
sor function and that both H- and K-Ras contribute to the path-
ogenesis caused by RASAL2 inactivation.
RASAL2 Inactivation Promotes Migration, Invasion,
and Tumor Progression
To fully characterize the oncogenic effects of RASAL2 loss, we
investigated whether RASAL2 suppression might also promote
migration, invasion, and tumor progression. RASAL2 suppres-
sion promoted themigration ofMCF10A cells in a wound-healing
assay (Figures 4A and 4B) and significantly enhanced invasion
through Matrigel (Figure 4C, p = 0.002). Similar to what was
observed in colony assays shown in Figure 3E, ablation of
HRAS or KRAS reduced invasiveness (Figure S1). We also uti-
lized a xenograft model of breast cancer progression thatmimics
the progression of ductal carcinoma in situ (DCIS) to invasive
carcinoma (Miller et al., 2000; Hu et al., 2008). Specifically,
MCF10ADCIS cells, derivatives of MCF10A cells that are en-
riched for a progenitor population of cells (Miller et al., 2000),
develop into DCIS-like lesions when grown as xenografts in
mice. However, after a latency of approximately 8 weeks, they
progress to invasive carcinoma, characterized by the loss of
the myoepithelial cell layer and basement membrane (Hu et al.,
2008). We acutely inactivated RASAL2, using two distinct
shRNAs in these cells, and found that RASAL2 inactivation
accelerated tumor progression, resulting in a rapid disruption
of the myoepithelium and basement membrane and thencer Cell 24, 365–378, September 9, 2013 ª2013 Elsevier Inc. 367
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Figure 2. RASAL2 Functions as a Tumor Suppressor in Breast Cancer
(A) Growth curves of MDA-MB-361 andMCF7 cells expressing RASAL2 or LacZ. Data points show triplicate averages ± SD. There were no statistically significant
differences in proliferation. Western blot on right confirms ectopic RASAL2 expression.
(B) Soft agar colony formation of MCF7, BT474, MDA-MB-361, and SUM159PT cells expressing RASAL2 or LacZ. Data show relative number of colonies ± SD.
There was a statistically significant decrease in anchorage-independent growth upon ectopic RASAL2 expression in RAS wild-type cell lines (MCF7 and
BT474 p < 0.0001; MDA-MB-361 p = 0.002), but not in the HRAS mutant cell line SUM159PT. Western blots confirm ectopic RASAL2 expression.
(C) Xenograft tumor formation of MDA-MB-361 andMDA-MB-231 cells expressing RASAL2 or LacZ. MDA-MB-361 cells were injected orthotopically into female
NOD/SCIDmice; MDA-MB-231 cells were injected subcutaneously into female nude mice. Horizontal bars indicate mean tumor volume. There was a statistically
significant decrease in tumor growth upon ectopic RASAL2 expression (p < 0.0001) in the RAS wild-type cell line MDA-MB-361, but not in the KRASmutant cell
line MDA-MB-231. Western blots below confirm ectopic RASAL2 expression.
(D) Xenograft tumor formation of CAMA1 cells infected with shRNAs targeting RASAL2 or nontargeting control shRNA and injected subcutaneously into female
NOD/SCID mice. Horizontal bars indicate mean tumor volume. There was a statistically significant increase in tumor growth upon RASAL2 inactivation (p =
0.0007). Western blot confirms RASAL2 knockdown.
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A Figure 3. RASAL2 Functions as a Tumor
Suppressor via Its Effects on Ras
(A) Soft agar colony formation of MCF7 cells ex-
pressing HA-tagged LacZ, wild-type, or mutant
RASAL2 (see also Table S3). Data show relative
number of colonies ± SD. *p% 0.05. Western blot
confirms expression of constructs.
(B) Western blot reflecting the relative activation of
the Ras/ERK pathway in the presence of HA-tag-
ged wild-type or mutant RASAL2. The pERK/ERK
ratio of each sample was calculated and normal-
ized to the vector control.
(C) Phospho-ERK (pERK) expression in MDA-MB-
361 xenograft tumors. LacZ, RASAL2, or mutant
RASAL2 was expressed in MDA-MB-361 cells,
and cells were injected orthotopically into female
NOD/SCID mice. pERK levels were assessed by
immunohistochemistry.
(D) Western blot showing HRas-GTP and KRas-
GTP levels in MCF10A cells following shRNA-
mediated inactivation of RASAL2 or control
shRNA. As indicated by the asterisk, the blot
confirming RASAL2 knockdown is a duplicate from
Figure 1E, as these immunoblots were generated
from the same samples.
(E) Soft agar colony formation of BT474 cells in-
fected with an shRNA targeting HRAS or KRAS or
a nontargeting control. Data show relative number
of colonies ± SD. Western blot confirms Ras iso-
form-specific knockdown.
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RASAL2: A Tumor Suppressor that Regulates Rasdevelopment of invasive adenocarcinoma after just 3 weeks
(Figure 4D). These results suggest that RASAL2 inactivation
may also play a role in breast cancer progression. Notably,
tumors in which RASAL2 had been depleted also exhibited a
marked elevation of phospho-ERK as compared to control
tumors (Figure 4E).
Loss of Rasal2 Promotes Metastasis and Ras Activation
in a Genetically Engineered Mouse Model of Luminal
Breast Cancer
As a rigorous and complementary means of investigating the
biological consequences of RASAL2 inactivation in vivo, we
generated genetically engineered mice that lack Rasal2. Mouse
embryonic stem cells that contain a gene-trap cassette within
the third intron of Rasal2 were used to generate Rasal2-deficient
mice (Figure 5A). Appropriate integration and loss of Rasal2
expression were confirmed in heterozygous and homozygous
mutant animals (Figures 5B and 5C).Rasal2/mice were viable,Cancer Cell 24, 365–378, Sfertile, and born at Mendelian ratios. We
found that mutant animals did exhibit
shorter overall survival as compared to
control animals (77.8 compared to
95.6 weeks; p = 0.007, Figure S2A). How-
ever, there was no obvious difference in
phenotype between wild-type and
Rasal2/ mice. A subset of animals
from both cohorts developed tumors
associated with old age. Whereas Rasal2
mutant mice developed these tumors
earlier, the tumor spectrum was similarto wild-type animals, and they did not develop mammary lesions
(Figure S2B). These results indicate that Rasal2 loss is not suffi-
cient to drive breast cancer in mice but may play a more general
role in enhancing the development of other spontaneous tumors.
To examine the effects of RASAL2 loss on mammary tumori-
genesis, we crossed Rasal2/ mice to animals that constitu-
tively overexpress a wild-type Her2 (Erbb2) transgene in the
mammary epithelium (MMTVneu mice) (Guy et al., 1992): a
mouse model of luminal tumors (Herschkowitz et al., 2007).
These tumors exhibit some differences from human luminal can-
cers, as they do not express estrogen receptor; however, unsu-
pervised hierarchical clustering analysis and tumor pathology
demonstrate that lesions from these animals recapitulate many
of the key features of human luminal tumors (Guy et al., 1992;
Herschkowitz et al., 2007). As such, these animals are currently
the best available genetically engineered mouse model for
luminal cancer (Guy et al., 1992; Herschkowitz et al., 2007). Fe-
male MMTVneu mice develop focal luminal mammary tumors,eptember 9, 2013 ª2013 Elsevier Inc. 369
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Figure 4. RASAL2 Inactivation Promotes
Migration, Invasion, and Tumor Progression
(A) Cell migration of MCF10A cells infected with
shRNAs targeting RASAL2 or a nontargeting
control.
(B)Western blot confirming RASAL2 knockdown in
MCF10A cells used in (A) and (C).
(C) Transwell invasion of MCF10A cells infected
with an shRNA targetingRASAL2 or a nontargeting
control. Invasion was measured after 24 hr and
reported as average ± SD (p = 0.002).
(D) Xenograft tumor progression of MCF10ADCIS
cells infected with shRNAs targeting RASAL2 or a
nontargeting control. Top: H&E images of xeno-
graft tumors. Bottom left: quantification of xeno-
graft tumor progression. Bottom right: western
blot confirming RASAL2 knockdown.
(E) Phospho-ERK (pERK) expression in
MCF10ADCIS xenograft tumors from (D) as as-
sessed via immunohistochemistry.
See also Figure S1.
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RASAL2: A Tumor Suppressor that Regulates Rasand a fraction of tumor-bearing females develop lung metasta-
ses (Guy et al., 1992). As expected, MMTVneu and MMTVneu;
Rasal2/ compound mice developed mammary adenocarci-
nomas and did so at a similar high frequency (Figure 5D, top
panels; Figure S2E). Strikingly, however, we found that
MMTVneu; Rasal2/mice developed substantially moremetas-
tases than MMTVneu animals. First, a higher fraction of com-
pound mutant mice developed lung metastases (Figure 5E,
74% versus 46%, p = 0.05). Second, compound mutant mice
developed more metastases per lung than MMTVneu animals
(Figure 5E, 30 per mouse versus 8 per mouse, p = 0.04). Finally,
the metastases were significantly larger inMMTVneu; Rasal2/
mice as compared toMMTVneumice (Figure 5D, bottom panels;
Figure 5E, p = 0.04). Interestingly, a subset of compound mutant
mice developed tumors that metastasized to other organs,
including brain, kidney, ovary, and gastrointestinal tract, a phe-
nomenon not observed in MMTVneu animals historically or in
our cohort (Figure 5F). Moreover, in most autochthonous mouse
models of mammary adenocarcinoma, metastasis is typically
limited to the lung and occasionally lymph nodes (Kim and
Baek, 2010). However, human breast cancers do frequently
metastasize to the brain and these other distal sites, underscor-
ing the significance of these observations and the potential utility
of this mouse model (Weigelt et al., 2005). Despite the dramatic370 Cancer Cell 24, 365–378, September 9, 2013 ª2013 Elsevier Inc.increase in metastasis, no differences in
primary tumor incidence, growth rate, or
tumor size were observed in MMTVneu
versus MMTVneu; Rasal2/ mice, indi-
cating that the differences in metastatic
burden were not due to underlying differ-
ences in primary tumor onset or growth
(Figures S2C, S2D, and S2F). Importantly,
when we compared primary tumors
from MMTVneu; Rasal2/ mice and
MMTVneu animals, higher levels of phos-
pho-ERK and phospho-AKT were more
consistently observed in MMTVneu;Rasal2/ lesions (Figure 5G). In addition, we found that Rasal2
was spontaneously lost or suppressed in a subset of MMTVneu
tumors, and this loss or suppressionwas accompanied by a sub-
stantial increase in phospho-ERK and phospho-AKT levels (Fig-
ure 5G). Finally, the primary tumor that spontaneously lost/sup-
pressed Rasal2 and exhibited the most robust activation of the
Ras pathway was a metastatic outlier within the MMTVneu
cohort (Tumor 6, Figure 5G; Figure S2G). Taken together, these
findings indicate that Rasal2 loss enhances Ras activity in mam-
mary tumors and that it promotes tumor progression, invasion,
and metastasis in both autochthonous mouse models of breast
cancer and human xenografts.
RASAL2 in Primary Human Breast Cancers
Genomic analyses demonstrate that RASAL2 mutations do
occur in human breast cancer but are relatively rare (Bamford
et al., 2004; Sjo¨blom et al., 2006; Shah et al., 2012; Table S1).
However, the two other known RasGAP tumor suppressors
appear to be more frequently inactivated in cancer via nonge-
netic mechanisms. To more accurately determine how
frequently RASAL2 is lost or suppressed in human breast can-
cers, we directly examined RASAL2 protein levels in primary hu-
man tumors. Existing RASAL2 antibodies cannot be used for
immunohistochemistry; therefore, we obtained breast cancer
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RASAL2: A Tumor Suppressor that Regulates Rasarrays comprised of 55 sets of protein lysates (in triplicate) from
matched primary breast tumors and adjacent normal mammary
tissue taken from naive patients (Mueller et al., 2010). These
tumor samples were histologically verified to contain at least
80% cancer cells and the normal tissue is cancer cell free. We
first validated our purified RASAL2 antibody in this assay and
found that dot blots from RASAL2-expressing and nonexpress-
ing human breast cancer cell lines exhibited the expected
pattern of expression (Figure 6A, top). RASAL2-specific shRNA
sequences also effectively ablated expression in this assay (Fig-
ure 6A, bottom). Using the tumor arrays, we found that RASAL2
expression was decreased by 75%–100% in 20% of human
breast tumors as compared to adjacent normal mammary tissue
(Figures 6B and 6C). These results confirm our findings in breast
cancer cell lines, suggesting that RASAL2 expression is lost or
suppressed in a significant fraction of human breast cancers at
a frequency that ismuch greater than indicated bymutation anal-
ysis alone. More importantly, however, low RASAL2 protein
levels were significantly associated with metastasis (Figures
6C and 6D, p = 0.006).
Because the cell line analysis indicated that RASAL2 expres-
sionwas low or undetectable in a subset of luminal breast cancer
cell lines (Figure 1), and mouse modeling studies further demon-
strated that RASAL2 loss promoted the metastasis of luminal tu-
mors, we evaluated RASAL2 expression in different breast can-
cer subtypes. Human breast cancers can be molecularly
classified into five distinct subtypes: basal-like, HER2-positive,
luminal A, luminal B, and normal breast-like (Perou et al., 2000;
Sørlie et al., 2001; Hu et al., 2006). Notably, molecular subtype
association analysis of transcriptional profiles from primary
breast cancers revealed that RASAL2 expression was low in
luminal B breast cancers; 50% of luminal B tumors expressed
the lowest levels of RASAL2, consistent with a potential role
for RASAL2 loss in this subtype (Figures 6E and 6F). Moreover,
low RASAL2 expression was also associated with both
increased tumor recurrence (Figure 6G, log rank p = 0.0133)
and decreased overall survival (Figure 6H, log rank p = 0.0131)
in patients with luminal B cancers. Finally, using publicly avail-
able TCGA methylation 450 data, we found that two CpG sites
in the RASAL2 promoter region are differentially methylated in
primary breast tumors. Specifically, RASAL2 promoter methyl-
ation is enriched in luminal B tumors (p < 0.05, Mann-Whitney
U test). These luminal B tumors also showed the lowest expres-
sion of RASAL2. Notably, both sites exhibit a significant increase
in methylation when comparing luminal B samples with the
lowest expression of RASAL2 (bottom 33%) to luminal B sam-
ples with highest expression (top 33%) (p < 0.05, t test). Taken
together, cellular, xenograft, mousemodeling, and human tumor
studies suggest that RASAL2 loss promotes breast cancer
development and metastasis and may play a particularly impor-
tant role in the progression of luminal B tumors. In this context,
the general lack of KRAS amplifications in luminal tumors but
their frequent occurrence in basal-like breast cancers is notable
(Cancer Genome Atlas Network, 2012), suggesting that RASAL2
suppression may provide an alternative mechanism of Ras acti-
vation in the luminal subtype. Nevertheless, although the models
used in this study provide functional evidence to support a role
for RASAL2 inactivation in luminal B tumors, these data do not
preclude its involvement in a fraction of other subtypes.CaRasal2 Mutations Promote Tumor Development
and Widespread Metastasis in p53 Mutant Mice
To determinewhetherRASAL2 inactivationmight also contribute
to the development of other sporadic tumors, Rasal2/ mice
were crossed to mice mutant for p53, one of the most commonly
inactivated tumor suppressors in human cancer (Vousden and
Lane, 2007). Trp53 mutant mice develop a spectrum of lym-
phomas and sarcomas, and some carcinomas arise in heterozy-
gotes (Donehower et al., 1992; Jacks et al., 1994). In addition to
the classical tumors observed in Trp53 mutant mice, Rasal2/
Trp53 compound mutant mice developed several other lesions
that were not found in Trp53 mutant controls, historically or in
our cohort (Figure 7A). Specifically, Rasal2/Trp53 mutant mice
developed hepatocellular carcinomas and other liver tumors,
colonic adenomas, and oral and stomach tumors (Figure 7A).
These findings are of particular interest because RASAL2muta-
tions have been found in related human cancers, namely, hepa-
tocellular carcinoma, colorectal carcinoma, head and neck
squamous cell carcinoma, and stomach cancer (Table S2).
Notably, the Rasal2/; p53/ tumors exhibited higher levels
of pERK as compared to Rasal2+/+; p53/ tumors (Figure 7B).
However, the most striking phenotype in Rasal2/Trp53mutant
mice was that Rasal2 loss potently promoted metastasis. The
Trp53/mice, either with or without functional Rasal2, typically
died from the primary tumor, which was frequently lymphoma.
Nevertheless, 60% of the solid tumors that developed in
Rasal2+/; Trp53+/ mice and 83% of the solid tumors from
Rasal2/; Trp53+/ mice were metastatic, as compared to
18% of tumors in Trp53+/ mice (Figure 7C, p = 0.003). Specif-
ically, Rasal2/Trp53mutant animals developed highly metastatic
mammary adenocarcinomas, hepatocellular carcinomas, lung
adenocarcinomas, and various sarcomas, again tumor types in
which RASAL2 mutations have been detected in humans (Fig-
ure 7D). Thus, these findings further underscore the role of
RASAL2 loss as a driver of metastasis and suggest that its inac-
tivation may play a role in the progression of breast and other
human cancers.
DISCUSSION
The Ras pathway plays a well-established role in cancer (Down-
ward, 2003). However, the primary mechanism(s) by which Ras
becomes activated in breast cancers has remained elusive.
Here, we report that RASAL2, which encodes a RasGAP, func-
tions as a tumor and metastasis suppressor in breast and other
cancers. Specifically, we have shown that loss-of-functionmuta-
tions in RASAL2 are found in human breast cancers and other
tumor types; however, like other RasGAP genes RASAL2 ap-
pears to be more frequently inactivated by nongenetic mecha-
nisms, and it is substantially repressed in at least 20% of primary
human breast cancers. We also showed that RASAL2 ablation
promotes tumor growth and progression in two different human
xenograft models, whereas RASAL2 reconstitution suppresses
mammary tumor growth. Notably, RASAL2 mutations activate
Ras and dramatically enhance metastasis in a genetically engi-
neered mouse model of luminal mammary cancer. RASAL2mu-
tations also cooperate with p53mutations to promote the devel-
opment and metastasis of several tumor types, including
mammary tumors, in a second mouse model. Finally, we showncer Cell 24, 365–378, September 9, 2013 ª2013 Elsevier Inc. 371
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Figure 5. Loss of Rasal2 Promotes Metastasis and Ras Activation in a Genetically Engineered Mouse Model of Breast Cancer
(A) Schematic of Rasal2 genomic locus and pNMDi4 genetrap cassette. Unshaded regions in exons 1 and 18 mark 50 and 30 UTRs, respectively. Known domains
of Rasal2 are noted (PH, C2, and RasGAP). See the Experimental Procedures for detailed description of pNMDi4. The genetrap cassette targets the third intron of
Rasal2.
(B) Genotyping of Rasal2 mice to distinguish wild-type (WT), heterozygous mutant (het), and homozygous mutant (hom).
(C) Western blot confirming loss of Rasal2 protein in genetrap animals (mammary gland tissue). WT, wild-type; het, heterozygous; hom, homozygous
mutant.
(D) Top: H&E images of primary mammary adenocarcinomas from MMTVneu; Rasal2+/+ and MMTVneu; Rasal2/ animals. Bottom: H&E images of lung
metastases from MMTVneu; Rasal2+/+ and MMTVneu; Rasal2/ animals. M, metastases.
(E) Lung metastasis burden in MMTVneu; Rasal2+/+ and MMTVneu; Rasal2/ animals. Lung metastasis incidence: percent of tumor-bearing females with lung
metastases at sacrifice (p = 0.05; n = 24 MMTVneu; Rasal2+/+, n = 23 MMTVneu; Rasal2/). Average number of lung metastases per animal: counted per
(legend continued on next page)
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breast cancer.
Notably, the lowest RASAL2messenger RNA (mRNA) expres-
sion levels are most frequently observed in luminal B human
breast cancers and are associated with recurrence and reduced
survival of patients with this tumor subtype. Collectively, these
data suggest that RASAL2 loss plays a causal role in breast can-
cer pathogenesis. Whereas the breast cancer xenograft studies
and the overall increase in tumor incidence in Rasal2/p53 mice
suggest that RASAL2 may play a role in primary tumor develop-
ment, the dramatic metastatic phenotype in Rasal2/MMTVneu
and Rasal2/p53mutant animals demonstrates a role for RASAL2
loss in metastasis. Similarly, the Ras pathway has been shown to
play a role in both primary tumor development and metastasis,
depending on context. As such, we hypothesize that RASAL2
inactivation may play a role in one or both processes, depending
on the presence of other mutations in a given tumor. Neverthe-
less, the human breast cancer data presented in this study sug-
gest that RASAL2 loss may play a more prominent role in pro-
gression and metastasis in this tumor type.
It should be noted that although RAS mutations are rare in
breast cancer, they do occur. Moreover, amplifications of wild-
type RAS are frequently observed in basal breast cancers, the
most aggressive subtype of human breast cancer, underscoring
the connection between Ras activation and breast cancer pro-
gression (Cancer Genome Atlas Network, 2012). Our data indi-
cate that overall RASAL2 is suppressed or lost in at least 20%
of human breast cancers. However, expression and DNA
methylation analysis of different breast cancer subtypes sug-
gests that RASAL2 loss may play a particularly important role
in the progression of luminal B tumors. The observation that
RASAL2 ablation promotes metastasis in a mouse model of
luminal tumors provides important functional data to support
this conclusion. In this respect, the fact that luminal B tumors
have poorer outcomes than luminal A tumors is notable; howev-
er, the mechanism(s) that drive the progression of these tumors
is largely unknown. Our data suggest that RASAL2 loss/suppres-
sion may play a causal role in the progression of this subtype,
although these observations do not preclude its potential
involvement in other subtypes.
Finally, whereas RASAL2 is mutated in breast cancer and in
other human tumors, it appears to be more commonly inacti-
vated via nonmutational mechanisms. Notably, the other Ras-
GAP tumor suppressors, NF1 and DAB2IP, are also inactivated
by both genetic and several nongenetic mechanisms (McGilli-
cuddy et al., 2009; Min et al., 2010). Similarly, PTEN and INPP4B,
two other tumor suppressors that negatively regulate an overlap-
ping set of signals, are also suppressed by multiple mechanisms
in cancer, some of which have not yet been elucidated (Gewinner
et al., 2009; Song et al., 2012). As such, loss of PTEN protein
expression, rather than mutational status or copy number, is
often evaluated in clinical samples during clinical trials and for
pathological staging (Thomas et al., 2004). The observationrepresentative section of lungs for each tumor-bearing female (p = 0.04). Averag
sentative section of lung for each tumor-bearing female (arbitrary units; p = 0.04
(F) H&E images of metastases to brain (a), gut (b), ovary (c), and kidney (d) in com
(G)Western blot analysis of phospho-ERK (pERK) and phospho-AKT (pAKT) levels
and MMTVneu; Rasal2/ animals (numbers 10–18).
Cathat RASAL2 loss plays a causal role in breast cancer progres-
sion and metastasis in animal models and that RASAL2 expres-
sion is lowest in primary human tumors that ultimately progress
or recur, suggests that RASAL2 could be useful as a prognostic
biomarker, in at least a subset of breast cancers, such as luminal
B tumors. Regardless, these studies have identified an important
tumor suppressor involved in breast cancer progression and
have revealed an alternative mechanism by which Ras becomes
activated in this disease.
EXPERIMENTAL PROCEDURES
Cell Culture and DNA Constructs
MEFs were immortalized as described previously (Johannessen et al., 2005).
MCF7, MCF10A, and MDA-MB-361 cells were purchased from American
Type Culture Collection. BT549, HS578T, MDA-MB-231, MDA-MB-453,
MDA-MB-468, SKBR3, T47D, and ZR-75-1 cells were obtained from Dr. Wil-
liam Hahn (Dana-Farber Cancer Institute). SUM149PT, SUM159PT,
SUM1315MO, and BT474 cells were obtained fromDr. FrankMcCormick (Uni-
versity of California, San Francisco). CAMA1 cells were obtained from Dr. Mar-
cia Haigis (Harvard Medical School). MCF10ADCIS were provided by Dr. Fred
Miller (Karmanos Cancer Institute) and the Polyak laboratory.
shRNAs from the RNAi Consortium (Broad Institute, MIT) with the following
sequences were utilized: NF1 shRNA (50-TTATAAATAGCCTGGAAAAGG-30 ),
RASAL2 shRNA1 (50-CCCTCGTGTTCTTGCTGATAT-30), RASAL2 shRNA2
(50-GCCTTCCACCTCTTCATAGTA-30 ), KRAS shRNA (50- CAGTTGAGACCT
TCTAATTGG-30), and HRAS shRNA (50- GACGTGCCTGTTGGACATCCT-30).
A scrambled shRNA was purchased from Addgene (50-CCTAAGGTTAA
GTCGCCCTCG-30). A RASAL2-targeting shRNA was cloned into the pLKO
vector (shRNA3) (50-ATGGAGTGCAATAGGACATTG-30). The Mammalian
Gene Collection fully sequenced human RASAL2 complementary DNA
(cDNA) was purchased from Open Biosystems (cat. number MHS4426-
99623118) and was cloned into the pHAGE-N-Flag-HA lentiviral expression
vector (Dr. J. Wade Harper, Harvard Medical School) for expression in cell
lines. Infections and transfections were performed as described in the Supple-
mental Experimental Procedures.
Proliferation, soft agar, migration, and in vitro invasion assays are described
in the Supplemental Experimental Procedures.
Xenograft Assays
Female nude and NOD/SCID mice were purchased from Charles River Labo-
ratories (cat. numbers 088 and 394, respectively) for subcutaneous xenograft
experiments. Cells were injected with Matrigel (BD Biosciences, cat. number
354234) as follows: MCF10ADCIS (1 3 105 cells, 50% matrigel, nude mice),
MDA-MB-231 (1 3 106 cells, 50% matrigel, nude mice), and CAMA1 (2 3
106 cells, 50% matrigel, NOD/SCID mice). For mammary fat pad orthotopic
xenograft experiments, 13 106 MDA-MB-361 cells were injected in 50% ma-
trigel bilaterally into the fourth mammary glands of female NOD/SCID mice
(Jackson Laboratories). Tumor size was measured by caliper, and tumor vol-
ume was calculated using the formula of volume = (length 3 width2) 3 p/6.
MCF10ADCIS Invasion Assay
RASAL2 expression was ablated in MCF10ADCIS cells using two distinct
shRNAs, and loss of RASAL2 expression was confirmed by immunoblot. Fe-
male nude (nu/nu) micewere injected subcutaneously with 100,000 shRASAL2
or shScramble control cells. Five or six tumors of each genotype (Scramble
shRNA, RASAL2 shRNA1, or RASAL2 shRNA2) were harvested after 3 weeks,
fixed, and stained with hematoxylin and eosin (H&E) to assess tumor
morphology. A pathologist scored a tumor as an invasive carcinoma if it wase metastasis burden per animal: average total area of metastasis in a repre-
). See also Figure S2.
pound tumor-bearing females. M indicates regions of metastasis.
in primary mammary tumors fromMMTVneu;Rasal2+/+ animals (numbers 1–9)
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Figure 6. RASAL2 Expression Is Lost/Low in Primary Human Breast Cancers, and Low Levels Are Associated with Metastasis and
Recurrence
(A) RASAL2 dot blot of whole-cell RIPA extracts from human breast cancer cell lines with high or low RASAL2 expression (MDA-MB-231 ‘‘231’’ and T47D,
respectively) (top) or MCF10ADCIS cells infected with control or RASAL2-targeting shRNAs (bottom).
(legend continued on next page)
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disruption of the myoepithelium and basement membrane.
Rasal2 Mutant Mice
All animal procedures were approved by the Center for Animal and Compara-
tive Medicine at Harvard Medical School in accordance with the National Insti-
tutes of Health Guildelines for the Care and Use of Laboratory Animals and the
Animal Welfare Act.
A mouse embryonic stem cell line in which the pNMDi4 genetrap cassette
targets Rasal2 was purchased from the Toronto Centre for Phenogenomics/
Canadian Mouse Mutant Repository (clone CMHD 463C12). The pNMDi4
genetrap cassette contains the following elements as depicted in Figure 4A:
HA 3/5 SA (splice acceptor), FL (flexible linker), Venus (enhanced yellow fluo-
rescent gene) with stop codon, loxP sites, pA (polyadenylation signal), PGK
(promoter), neo (neomycin resistance gene) with stop codon, and HPRT SD
(splice donor). The neomycin resistance gene stop codon prevents translation
of 30 exons. The presence of the genetrap cassette within the third intron of
Rasal2 was confirmed using cDNA PCR. Chimeric mice were generated and
crossed to C57BL/6-E animals (Charles River Laboratories), and pups were
tested for presence of the genetrap. Two additional copies of the genetrap
cassette elsewhere in the genome were discovered in the mouse ES cell line
and genetrap mice. Genetrap-positive mice were crossed to wild-type ani-
mals, and Southern blotting was used to identify pups that had the genetrap
cassette only within the Rasal2 locus (data not shown). These animals were
used as founders for all cohorts and subsequent crosses.
Rasal2 Genotyping
Primers for PCR of the genetrap cassette were NMD.F (50-
CATGGTCCTGCTGGAGTTC-30) and NMD.R (50-TGCCTTTAGACCTTTTTGT
GG-30). Total RNA was extracted from homogenized tails using QiaShredder
and RNeasy kits (QIAGEN), and cDNA was synthesized using qScript cDNA
Synthesis Kit (Quanta). PCR was performed on cDNA with primers NeoL (50-
GCTATCAGGACATAGCGTTGGCTAC-30 ), GT463C12_F3 (50-TCGGATCCTTC
TGGAGTCAG-30), and GT463C12_R1 (50-CTCTCTCGGAGGCAGAGCTA-30)
to detect wild-type (F3/R1) and mutant (NeoL/R1) transcripts.
Compound Mutant Mice
Rasal2 genetrap mice were crossed to FVB/N-Tg(MMTVneu)202Mul/J mice
(Jackson Laboratories, cat. number 002376) (Guy et al., 1992) or to
B6.129S2-Trp53Tm1Tyj/J mice (Jackson Laboratories, cat. number 002101)
(Jacks et al., 1994). Cohorts of Rasal2 mutant mice and controls were on a
129-enriched background (75% 129SvImJ, 25% C57BL6). Cohorts of Trp53;
Rasal2 compound mice and controls were on a mixed 129/B6 background
(62.5% C57BL6, 37.5% 129SvImJ). Cohorts of MMTVneu; Rasal2 compound
mice and controls were on a background of 56% 129SvImJ, 25% FVB, and
19% C57BL6.
Protein Lysates and Western Blot Analyses
Protein extracts were isolated from cells or homogenized tissue in 1% SDS
boiling lysis buffer. Ras-GTP levels were determined using a Ras Activation
Assay Kit (EMD Millipore). The following antibodies were used for immuno-
blots: actin (Sigma, cat. number A2066), phospho-AKT (Ser473, Cell Signaling,
cat. number 4060), AKT (Cell Signaling, cat. number 9272), ER (Thermo, cat.
number R9101-SO), phospho-ERK (Thr202/Thr204, Cell Signaling, cat. num-(B) Dot blot images from human breast tumor lysate array. Six sets of RASAL2 and
(right) and triplicate spots of paired normal tissue lysate (left).
(C) Quantification of RASAL2 expression in tumor lysate arrays. Each bar depicts
matched normal control as described in the Experimental Procedures. Red bars
(D) RASAL2 protein expression in tumor versus normal in nonmetastatic (stages
change in RASAL2 protein expression in tumor versus normal. Data are reported
(E) Heatmap of RASAL2 gene expression as a function of robust molecular subt
tumor subtype. Percentages of tumors with high, intermediate, and low RASAL2
(F) RASAL2 expression table. For each breast cancer subtype, the number of sam
expression are indicated.
(G) Kaplan-Meier curve showing recurrence-free survival of luminal B tumors wit
(H) Kaplan-Meier curve showing overall survival of luminal B tumors with high or
Caber 4370), ERK (Cell Signaling, cat. number 9102), GAPDH (Cell Signaling,
cat. number 2118), HA (Covance, cat. number MMS-101P), HER2 (Cell
Signaling, cat. number 2242), NF1 (UP69 C-terminal polyclonal antibody)
(McGillicuddy et al., 2009), p120RasGAP (BD Transduction Laboratories,
cat. number 610040), HRas (Santa Cruz, cat. number SC-520), KRas (Santa
Cruz, cat. number SC-30), panRas (Upstate, cat. number 05-516), a-tubulin
(Sigma, cat. number T5168), b-tubulin (Sigma, cat. number T4026), and Vincu-
lin (Cell Signaling, cat. number 4650). A peptide antigen (NP_773793 amino
acids 1111–1130) was used to generate and affinity purify an anti-RASAL2
rabbit polyclonal antibody (Covance ImmunoTechnologies). For RASAL2,
reconstitution studies cells were typically plated in 5% serum overnight
36 hr posttransfection. pERK and ERK levels were assessed by western blot
and quantified using ImageJ software.
Immunohistochemistry was performed as described in the Supplemental
Experimental Procedures.
Mouse Tumor and Tissue Analysis
Tumors and tissues were fixed in buffered formalin, stored in 70% ethanol,
paraffin embedded, and sectioned. Sections were stained with hematoxylin
and eosin.
Human Tumor Lysate Array Analysis
Qualitative breast cancer tumor lysate arrays were purchased from Protein
Biotechnologies (cat. number PMA2-001-L). Samples were deidentified and
are not considered human subject research. Arrays were probed with the affin-
ity purified RASAL2 antibody. The RASAL2 antibody was validated for this
assay using tumor lysate arrays by probing nitrocellulose membranes spotted
with 1 mg/ml RIPA lysates from human breast cancer cell lines with or without
RASAL2. Developed film was scanned and quantified using ImageJ software.
Arrays were stained with Colloidal Gold and scanned, and total protein was
quantified using ImageJ. RASAL2 levels in each spot were normalized to the
Colloidal Gold level in the same spot. Triplicate spots were averaged, and
the ratio between the tumor normalized triplicate and normal normalized trip-
licate was calculated and reported as a Log2 fold change value.
Molecular Subtype Association and Survival Analysis
Gene expression correlations targeted analysis was applied on published
genomic data on patients classified in the same molecular subtype with the
six molecular subtype predictors (Sørlie et al., 2001; Hu et al., 2006), using
GenExMiner as previously described (Je´ze´quel et al., 2012). Samples were de-
identified and are not considered human subject research. A gene expression
map was determined by molecular subtype predictors (single sample predic-
tors [SSPs] and/or subtype clustering models [SCMs]). A gene expression
table was also provided for robust classifications, indicating for each subtype
the proportion of patient with low, intermediate, and high gene expression;
gene expression values were split in order to form three equal groups.
Gene expression data and relapse-free and overall survival information were
analyzed as previously described (Gyo¨rffy et al., 2010). Data were downloaded
from GEO (Affymetrix HGU133A and HGU133+2 microarrays), EGA, and
TCGA. The background database integrates gene expression and clinical
data simultaneously. To analyze the prognostic value of RASAL2, the
patient samples are split into two groups according to median expression of
RASAL2.total protein stains are shown. Each set contains triplicate spots of tumor lysate
the change in RASAL2 expression in one sample as compared to the sample’s
indicate metastatic samples.
I, II, and III) versus metastatic (stage IV) tumors. Graph shows the Log2 fold
as average ± 95% CI. p = 0.006.
ype predictor classification, which is based on patients classified in the same
expression per molecular subtype are given in the gene expression table.
ples and percentage of samples with low, intermediate, or high RASAL2mRNA
h high or low RASAL2 expression (log rank p = 0.013).
low RASAL2 expression (log rank p = 0.013).
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Figure 7. Rasal2, Trp53 Compound Mutant Mice Develop Highly Metastatic Tumors
(A) Phenotypes in Rasal2/Trp53 compound mutant mice. Pie charts display the array of phenotypes in each genotype. Phenotypes observed in Rasal2 mutant
compoundmice, but not observed in control cohorts, are shown in color. n = 21Rasal2+/+; Trp53/, 18Rasal2+/; Trp53/, 31Rasal2/; Trp53/ 16Rasal2+/+;
Trp53+/, 21 Rasal2+/; Trp53+/, 21 Rasal2/; Trp53+/.
(B) Western blot analysis of phospho-ERK (pERK) levels in primary tumors from Rasal2+/+; Trp53/ and Rasal2/; Trp53/ compound mice.
(C) Percentage of metastatic solid tumors in Rasal2+/+, +/, and /; Trp53+/ compound mice. Increased metastasis in compound animals is statistically sig-
nificant (p = 0.003). The paucity of metastatic solid tumors in Trp53+/ mice is supported by historical data.
(D) Images of metastatic lesions (bottom) and the corresponding primary tumors (top). From left to right: Mammary adenocarcinoma and lung metastasis, os-
teosarcoma and livermetastasis, hepatocellular carcinoma and lungmetastasis, and lung adenocarcinoma and livermetastasis.M,metastasis; Lu, lung; Liv, liver.
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